11 clinical trials found.
-
A Phase 1 Open-label Preliminary Pharmacokinetics (PK)and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK)and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific ...Phase
TRIAL ROLE: Sub Investigator
-
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute LeukemiaPhase
TRIAL ROLE: Sub Investigator
-
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma Grade IIIb Follicular Lymphoma transformed lymphoma and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
This trial is a Phase II/III evaluation of CC-486 (oral azacitidine) added to R-mini-CHOP. The primary endpoint of the Phase II component is 1-year ...Phase
TRIAL ROLE: Sub Investigator
-
EVEREST-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
This is a first-in-human, seamless Phase 1/2, multicenter, open-label, nonrandomized study. This study consists of Phase 1 dose-escalation and dose-expansion portions and a Phase ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Multicenter Open-Label Study Of CC-97540 (BMS-986353) CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells in Participants with Severe Refractory Autoimmune Diseases: Systemic Lupus Erythematosus Idiopathic Inflammatory Myopathy or Systemic Sclerosis
SLE disease activity results in accumulation of tissue and organ damage (eg, nephritis, multisystem organ failure, and central nervous disease) that contributes to morbidity and ...Phase
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022 A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY
CD19-directed autologous CAR T-cell therapy has changed the treatment landscape for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Nonetheless, up to 60 ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Multicenter Open-Label Study of CB-010 a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
T cells are an integral part of the immune system that kills cancer cells in the body. T cells have been harvested from peripheral blood ...Phase
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-2100 IN PATIENTS WITH RECURRENT ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCRCC)
This is a study seeing if a new cellular medicine called AB-2100, a logic-gated CAR T cell targeting PSMA and Ca-IX, is effective for adult ...
Phase
TRIAL ROLE: Sub Investigator
-
EVEREST-2: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
econditioning lymphodepletion) for different cancers that express mesothelin (MSLN). First, the study team will test it on a small number of patients to see if ...
Phase
TRIAL ROLE: Sub Investigator
-
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
This is study is testing a new medicine called AFNT-211 for patients with advanced or metastatic (cancer that has spread) that has specific genetic markers ...
Phase
TRIAL ROLE: Sub Investigator
